Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemoradiotherapy with S-1 plus cisplatin for stage IA esophageal squamous cell carcinoma (SP-RT)
jRCTs051180078Phase 2Active, not recruiting
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenosquamous carcinoma (ASC) and esophageal basaloid squamous cell carcinoma (BSCC). Primary endpoints: Complete response rate without endoscopic surgery and 3-year survival rate with endoscopic surgery. Started Jun 2014; status: active, not recruiting.
02
Drugs
tegafurcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)esophageal basaloid squamous cell carcinoma (BSCC)
Beyond the preview
Go deeper on jRCTs051180078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180078.